These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1597 related articles for article (PubMed ID: 30785829)

  • 1. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
    Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
    J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
    N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
    N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
    Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
    Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
    Brahmer JR; Lee JS; Ciuleanu TE; Bernabe Caro R; Nishio M; Urban L; Audigier-Valette C; Lupinacci L; Sangha R; Pluzanski A; Burgers J; Mahave M; Ahmed S; Schoenfeld AJ; Paz-Ares LG; Reck M; Borghaei H; O'Byrne KJ; Gupta RG; Bushong J; Li L; Blum SI; Eccles LJ; Ramalingam SS
    J Clin Oncol; 2023 Feb; 41(6):1200-1212. PubMed ID: 36223558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
    Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
    O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS
    ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
    J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
    Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
    Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
    J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
    N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.
    Borghaei H; O'Byrne KJ; Paz-Ares L; Ciuleanu TE; Yu X; Pluzanski A; Nagrial A; Havel L; Kowalyszyn RD; Valette CA; Brahmer JR; Reck M; Ramalingam SS; Zhang L; Ntambwe I; Rabindran SK; Nathan FE; Balli D; Wu YL
    ESMO Open; 2023 Dec; 8(6):102065. PubMed ID: 37988950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
    Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
    Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
    Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
    Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
    Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
    Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
    Galsky MD; Saci A; Szabo PM; Han GC; Grossfeld G; Collette S; Siefker-Radtke A; Necchi A; Sharma P
    Clin Cancer Res; 2020 Oct; 26(19):5120-5128. PubMed ID: 32532789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
    JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.